Aadi Bioscience (Aadi Bioscience) Interest Expense : $-0.23 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aadi Bioscience's interest expense for the three months ended in Mar. 2024 was $ -0.06 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.23 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aadi Bioscience's Operating Income for the three months ended in Mar. 2024 was $ -19.51 Mil. Aadi Bioscience's Interest Expense for the three months ended in Mar. 2024 was $ -0.06 Mil. Aadi Bioscience did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aadi Bioscience Interest Expense Historical Data

The historical data trend for Aadi Bioscience's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Interest Expense Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.82

-0.67

-0.23

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial										-0.06	-0.06	-0.06	-0.06	-0.06

Aadi Bioscience Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.23 Mil.

Aadi Bioscience (NAS:AADI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aadi Bioscience's Interest Expense for the three months ended in Mar. 2024 was $-0.06 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-19.51 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.74 Mil.

Aadi Bioscience's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Aadi Bioscience did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Aadi Bioscience (Aadi Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (NAS:AADI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Executives

Neil Desai	director, officer: See Remarks	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
David James Lennon	director, officer: Chief Executive Officer	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Scott M. Giacobello	officer: Chief Financial Officer	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Lorettta M Itri	officer: Chief Medical Officer
Brendan Delaney	officer: Chief Operating Officer	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun	director	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault	officer: Chief Financial Officer
Behzad Aghazadeh	director, other: See Remarks	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc	director, other: See Remarks	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal	director	88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc	director, other: See Remarks	110 GREEN STREET, SUITE 800, NEW YORK NY 10012